Current Report · Items 2.02, 9.01 · 8-K

INTERPACE BIOSCIENCES INC

IDXGDOTCEQUITYCurrent

Results of Operations and Financial Condition

Filed Aug 12, 2026Accepted Aug 12, 2026, 4:15 PM EDTCIK 1054102Accession 0001493152-26-037360

Company context

We are a company that provides esoteric molecular diagnostic testing and pathology services to aid physicians in their evaluation of cancer risk in patients with indeterminate biopsies and a perceived risk of cancer from clinical features. We develop and commercialize genomic tests that can personalize medicine to help improve patient diagnosis and management. Due to the decision of CMS to cease reimbursement coverage of our PancraGEN® test for assessing the risk of pancreatic cyst progression to cancer on April 24, 2025 which resulted in specimens for first-line fluid chemistry and PancraGEN® testing not being accepted by the Company after May 2, 2025, we are currently concentrating our efforts on our molecular diagnostic tests for thyroid cancer, ThyGeNEXT® and ThyraMIR®v2.

Current securities

IDXGDOTC · EQUITY · Current

Historical securities (2)

IDGGWNASDAQ · WARRANT · Historical · closed Jun 21, 2022 IDXGOTC · EQUITY · Historical · closed Jun 21, 2022

Recent company filings

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 2.02 Results of Operations and Financial Condition. On August 10, 2026, Interpace Biosciences, Inc. issued a press release announcing its results of operations and financial condition for the quarter ended June 30, 2026. The full text of the press release is set forth as Exhibit 99.1 attached hereto and is incorporated herein by reference. The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.

Filed exhibits (1)

EX-99.1 (by filename) ex99-1.htm

EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results Q2 Revenue of $9.1 million Q2 Income from Continuing Operations of $0.3 million Q2 Thyroid volume year-over-year increase of 6% Q2 Thyroid revenue year-over-year increase of 9% Trailing twelve-month thyroid revenue of $36.1 million, an increase of 11% on a comparable thyroid-only basis PARSIPPANY, NJ, August 10, 2026 (GLOBE NEWSWIRE) - Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2026 and provided a business and financial update. Interpace generated Q2 2026 revenue of $9.1 million on 9% year-over-year thyroid revenue growth, delivered $0.3 million of income from continuing operations or 3% of revenue, which included approximately $0.2 million of non-recurring professional fees associated with the Company’s strategic and corporate initiatives, and produced Adjusted EBITDA of $0.7 million, or 8% of revenue. As previously disclosed, the Company discontinued its PancraGEN ® pancreatic testing business in May 2025 and now operates as a…

Open exhibit ↗